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Contribution of rare and common variants
to intellectual disability in a sub-isolate
of Northern Finland
Mitja I. Kurki1,2,3, Elmo Saarentaus 3, Olli Pietiläinen2,4, Padhraig Gormley 1,2, Dennis Lal1,2, Sini Kerminen3,
Minna Torniainen-Holm3,5, Eija Hämäläinen3, Elisa Rahikkala6,7,8, Riikka Keski-Filppula6,7,8, Merja Rauhala9,
Satu Korpi-Heikkilä9, Jonna Komulainen–Ebrahim10, Heli Helander10, Päivi Vieira10, Minna Männikkö11,12,
Markku Peltonen5, Aki S. Havulinna3,5, Veikko Salomaa 5, Matti Pirinen 3, Jaana Suvisaari 5,
Jukka S. Moilanen6,7,8, Jarmo Körkkö9, Outi Kuismin3,6,7,8, Mark J. Daly1,2,3,13,14 & Aarno Palotie1,2,3,13,14
The contribution of de novo variants in severe intellectual disability (ID) has been extensively
studied whereas the genetics of mild ID has been less characterized. To elucidate the
genetics of milder ID we studied 442 ID patients enriched for mild ID (>50%) from a
population isolate of Finland. Using exome sequencing, we show that rare damaging variants
in known ID genes are observed signiﬁcantly more often in severe (27%) than in mild ID
(13%) patients. We further observe a signiﬁcant enrichment of functional variants in genes
not yet associated with ID (OR: 2.1). We show that a common variant polygenic risk sig-
niﬁcantly contributes to ID. The heritability explained by polygenic risk score is the highest for
educational attainment (EDU) in mild ID (2.2%) but lower for more severe ID (0.6%). Finally,
we identify a Finland enriched homozygote variant in the CRADD ID associated gene.
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Intellectual disability (ID) is a relatively common disordercharacterized by deﬁcits in both intellectual and adaptivefunctioning in conceptual, social and practical domains. A
diagnosis of ID requires deﬁcits in a broad range of intellectual
functions, deﬁcits in adaptive functioning resulting in failure to
meet developmental and sociocultural standards for personal
independence and social responsibility, and an onset during the
developmental period1. The population prevalence estimates of
ID varies between 1 and 3% and is clearly lower (<0.5%) for more
severe forms of ID (IQ < 50) than for mild forms2.
While genome-wide studies using microarrays and exome
sequencing have identiﬁed a prominent role of de novo copy
number variations (CNVs), INDELs and single nucleotide var-
iants in mostly severe ID with reported diagnostic yields of
13–42%, their role in mild ID is less studied but expected to have
a less prominent role3,4. Intriguingly siblings of mild ID indivi-
duals have low IQ compared to the general population whereas
the IQ of siblings of severe ID individuals do not differ from the
general population5. Reichenberger et al.5 conclude that mild ID
represents a low extreme in a normal distribution of IQ, while
severe ID is a distinct condition with different etiology5.
The observation that intellectual disability has a high co-
morbidity with other neurodevelopmental and neuropsychiatric
diseases such as autism, schizophrenia, and epilepsy has stimu-
lated the hypothesis that these diseases might, in part, have shared
genetic backgrounds and thus alterations in the same pathways6.
One strategy to shed light on the genetic background of dis-
eases is to use populations where the incidence of the trait is
higher, and/or where the population history provides beneﬁts for
variant identiﬁcation. Finland is a well-characterized genetic
isolate where the small size of the founder population, subsequent
bottleneck effects, and genetic drift have caused an enrichment of
some rare and low-frequency variants as compared to other
European populations7,8. In a population with a recent bottle-
neck, such as Finland, variants conferring a high risk for a disease
with reduced fecundity can exist at markedly higher frequencies
than in older populations because negative selection has not had
time to drive down the allele frequencies, and therefore these
variants are easier to associate to a disease9.
Interestingly, ID (Fig. 1) and other neurodevelopmental and
neuropsychiatric diseases (NDD) like schizophrenia have a higher
prevalence in North-Eastern Finland as compared to South-
Western Finland10,11. It has been hypothesized that such a pattern
is related to the recent bottlenecks of these regions. The Eastern
and Northern parts of Finland were inhabited more permanently
only after the internal migration of small groups in the 16th
century while Southern coastal regions were already more popu-
lous (Fig. 1)12. The regional genetic differences between the early
and late settlements (east-west and north-south) can be clearly
recapitulated from genome-wide common SNP data13–15.
The aforementioned Finnish population history and the
observation of geographical differences in the prevalence of
neurodevelopmental diseases in Finland motivated us to initiate
the Northern Finland Intellectual Disability (NFID) study, a
geographically based cohort of ID patients and their family
members recruited from specialty clinics in the two most
Northern provinces of Finland. The only study exclusion criterion
was having a known or suspected genetic or environmental cause
for the phenotype and therefore the majority of our patients have
the most common mild form of ID. Here we describe a com-
prehensive genetic characterization of 442 independent NFID
patients with unknown disease etiology, enriched for mild
(51.4%) forms of ID.
We then examined the genetic architecture of this ID cohort
that has undergone a population bottleneck and has a high
proportion of mild ID cases. We studied the contribution of rare
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Fig. 1 ID prevalence estimates in different municipalities in Finland. The primary NFID collection municipalities of Northern Ostrobothnia, Kainuu and
Lapland are outlined in solid black. The approximate boundary between early and late settlements is shown with a dashed line
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variants using exome sequencing, common variant polygenic risk
scores, and CNVs using genome-wide association study (GWAS)
arrays, each for different ID severity categories. We then com-
pared the common and rare variants observed in the ID cohort to
a large collection of pre-existing Finnish exome (n= 11,311) and
GWAS array data (n= 11,699).
We also analyzed the geographical distribution of the poly-
genic risk variant load of educational attainment, IQ and schi-
zophrenia across different parts of Finland. Finally, to explore
the broader phenotypic impact of identiﬁed variant categories
and individual variants in the NFID cohort, we compared the
identiﬁed variants to 640 exome-sequenced individuals with
cognitive impairment, schizophrenia (SCZ) or autism spectrum
disorder (ASD).
We show that damaging variants in known ID genes are more
often identiﬁed in more severe ID than mild ID. We further show
that polygenic common variant burden is associated with all
severity forms of ID and the polygenic risk seems to act in
additive manner with rare damaging variants in known ID genes.
Results
Regional ID prevalence in Finland. We ﬁrst estimated the
regional prevalence of ID in Finland using the social security
disability beneﬁts register. We observed a higher prevalence of
individuals receiving disability beneﬁts for ID in the Eastern and
Northern parts of Finland as compared to Southern and Western
Finland (Fig. 1). The highest prevalence was observed in Kainuu
and North-Ostrobothnia, two of the primary municipalities of the
NFID patient collection (Fig. 1).
Mutations in known genes causing cognitive impairment. After
joint genotype calling and quality control, we analyzed the
exomes of 442 independent ID patients (Tables 1 and 2) and
2206 genetically matched population controls. Out of the 442
independent patients we had exome data for 138 full trios, 133
duos and the remaining 171 patients were cases only. To identify
individuals with a potential causative variant in the exome ana-
lysis, we ﬁrst searched for damaging missense or protein trun-
cating variants (PTV) in 818 known developmental delay genes
(see Materials and Methods and gene list in Supplementary
Data 1). For genes where autosomal recessive inheritance has
been reported, only homozygote variants were considered.
Within these 818 genes we identiﬁed a Likely pathogenic muta-
tion in 64 patients (Supplementary Data 2, see Supplementary
Data 3 for clinical details of each patient). For the subset of
individuals for which we had parental exome available (138 trios
and 133 duos), we further ﬁltered the list of Likely pathogenic
variants by not inherited from a parent without learning dis-
ability. This step ﬁltered 5/24 likely pathogenic variants in trios
and 0/15 in duos (Supplementary Data 2). We also excluded 1
Likely diagnostic variants when the clinical phenotype was clearly
different (assessed by clinical geneticist) than reported in the
literature. After these ﬁlterings we identiﬁed Likely pathogenic
diagnosis for 59/422 patients in exome sequencing.
When comparing the rate of likely pathogenic variants to the
2206 genetically matched controls, we observed the strongest
enrichment in PTV variants (OR: 10.94, 95% CI: 4.89–26.21,
p: 2.7e−10, Fisher’s exact test) followed by dominant acting (OR:
5.47, 95% CI: 3.19–9.38, p: 7.5e−12, Fisher’s exact test) and
recessive (OR: 1.83, 95% CI: 0.7–4.30, p: 1.4e−1, Fisher’s exact
test) constrained/damaging missense variant classes (Fig. 2).
Variants in novel cognitive impairment genes. Given that ~86%
of our cases did not have a variant affecting a known NDD gene,
we wanted to assess if there was a burden of rare variants outside
of known genes. We performed an enrichment analysis of var-
iants that were either PTV or constrained damaging missense
(MPC > 2) variants and not observed in the non-Finnish Gno-
mAD samples or in our internal Finnish controls (different
controls used for ﬁltering and enrichment, see Table 2). First, we
veriﬁed that there was no spurious enrichment of variants caused
by stratiﬁcation or batch effects by analyzing if there was an
enrichment of synonymous variants (not observed in GnomAD
or our Finnish controls) between cases and controls. No such
enrichment was observed, suggesting that QC and case control
matching were successful (Fig. 3).
Dominant PTVs in high pLI genes (OR: 2.65, 95% CI:
2.02–3.47, p: 2.2e−12, Fisher’s exact test) and constrained
damaging missense variants not seen in GnomAD or Finnish
controls within novel genes (OR: 1.64, 95% CI: 1.29–2.08,
Table 1 Patient clinical characteristics in the NFID sample
ID severity Mild Moderate Profound Undeﬁned
Total 259 126 72 41
Female % 37% 41% 36% 44%
Epilepsy 28 (11%) 19 (15%) 37 (51%) 9 (22%)
ASD 22 (8%) 17 (13%) 25 (35%) 3 (7%)
Behavioral
impairment
38 (15%) 28 (22%) 15 (21%) 0 (0%)
Psychotic disorder 24 (9%) 16 (13%) 8 (11%) 0 (0%)
Dysmorphism 85 (33%) 62 (49%) 41 (57%) 13 (32%)
ASD autism spectrum disorder
Table 2 Cohorts used in the analyses
Cases Controls
Analysis cohort Analyses N ID ASD SCZ EPI N
NFID (primary cohort) EXOME 442 442 62 47 92 2206b
PRS 439 439 62 47 86 2195b (matched)
14,816 (total)
CNV 433 433 57 47 84 1100b
NFNDD (Northern Finland NeuroDevelopmental Disorder) EXOME association analysis 314 17 40a 239 26 1548
SFNDD (Southern Finland NeuroDevelopmental Disorder) EXOME association analysis 322 14 73a 211 33 1594
SISU controls EXOME variant ﬁltering — — — — — 5922
Sample sizes are the numbers used in the analysis after quality control. The number of individuals in the analyses are after QC and after related individuals have been removed
ASD autism spectrum disorder, SCZ schizophrenia, EPI epilepsy, PRS Polygenic Risk Score, CNV copy number variant
aComorbidities were not available from ASD cohorts
bNone of the controls from the FINRISK study have any NDD (intellectual disability, autism, schizophrenia) or epilepsy and all controls are genetically matched to cases
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p: 5.9e−5, Fisher’s exact test) were signiﬁcantly enriched in cases
(Fig. 3). The signal for PTV variants was almost exclusively in
genes intolerant of PTV-mutations (pLI < 0.95, OR: 1.16, 95% CI:
0.94–1.44, 1.7e−1; Fig. 3). Homozygous PTVs (likely complete
knockout of a gene) in novel genes were over twofold enriched in
cases, but were not statistically signiﬁcant (OR 2.51, 95% CI:
0.40–11.78, p: 1.8e−1, Fisher’s exact test; Fig. 3).
Copy number variants. After QC (see Methods), we assessed the
contribution of likely diagnostic CNVs in 433 NFID patients and
1100 genetically matched controls. Deletions of any type (>100
kb) were observed slightly more often in cases than in controls
(OR: 1.3 (CI 0.94–1.7) p: 0.098, Fig. 4a: ncases= 85 (19.6%),
ncontrols= 177 (16.1%)). However, large deletions (>500 kb) were
more frequent in cases, regardless of chromosomal location (OR
4.4 (CI 2.4–8.3) p: 4.8e−7 (Fisher’s exact test), NFID: 31 indivi-
duals (7.2%), controls: 19 individuals (1.8%); Fig. 4b). CNVs that
have previously been associated with syndromes, or deleted a
known ID gene, were strongly enriched in cases (OR: 26.5 (CI
6.4–233.9), p: 4.4e−10, Fisher’s exact test) 20 patients (4.6%) vs.
two population controls (0.02%); Fig. 4a).
Using our classiﬁcation algorithm, we identiﬁed a Likely
pathogenic CNV in a total of 29 cases (Supplementary Data 4).
Large deletions (>1Mb) were the most commonly identiﬁed
likely pathogenic CNVs (21 cases, 4.9%; 7 controls 0.6%) (Fig. 4b).
A total of 17 cases (3.9%) and two controls (0.2%) carried a CNV
overlapping a region previously linked to syndromic ID (Fig. 4a).
A single 4.7 Mb duplication meeting pathogenicity criteria was
detected, overlapping the well-established Prader-Willi/Angel-
man syndrome region at 15q11-q13. The syndromic CNVs
identiﬁed in controls were non-ID associated (12p13.33 deletion)
and a region with known variable phenotype (22q11 duplication
syndrome16). Known ID-associated gene was deleted in 14 cases
(3.2%) and 0 controls (Fig. 4a). The distribution of duplication
sizes is presented in Fig. 4c.
As a pathogenic CNV was observed in only 29 cases (6.7%), we
analyzed if there was an excess of smaller deletions in genes
intolerant of PTV variations not previously associated with
cognitive phenotype. After removing likely pathogenic CNV
types, we observed such deletions in 12 cases (2.8%) and 9
controls (0.8%) (OR (CI 1.3 - 9.3), p: 5.8e-3, Fisher’s exact test)
(Fig. 4a and Supplementary Figure 5).
OR: 10.94, p :2.7e–10
OR: 5.47, p :2.7e–10
OR: 1.83, p :1.4e–01
OR: 0.91, p :8.0e–01
PTV
Case: 21/442(0.048)
Control: 10/2206(0.0045)
Missense dominant (MPC>2)
Case: 32/442(0.072)
Control: 31/2206(0.014)
Missense recessive (CADD>20)
Case: 8/442(0.018)
Control: 22/2206(0.01)
Synonymous
Case: 18/442(0.041)
Control: 98/2206(0.044)
0 10 20 30
Odds ratio (95% confidence intervals)
Fig. 2 Enrichment of likely pathogenic and synonymous variants in known ID genes. Enrichment of variants in 818 known ID genes (Methods) in NFID cases
compared to genetically matched controls. Heterozygotes were counted only for those genes for which a dominant inheritance mode is reported. The
number of carriers and total individuals are given on the left and in parenthesis the proportion of carriers. Circles indicate the odds ratio (OR) and lines
indicate 95% conﬁdence interval of the OR. The synonymous variant identiﬁcation comparison was performed to assess if possible differences in the
variant identiﬁcation rate due to batch/capture differences were adequately controlled. PTV protein truncating variant, CADD Combined Annotation-
Dependent Depletion pathogenicity score, pLI probability of loss of function intolerance. Source data are provided as a Source Data ﬁle
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Total genetic diagnosis rate. After combining exome and CNV
data, we identiﬁed a likely diagnosis for 80 (18.5%) patients
(Fig. 5a) of the 433 patients with both exome and CNV data
available). The strongest risk factor was having a PTV in a known
neurodevelopmental disorder gene (OR 11.1, 95% CI: 4.1–38.1, p:
3.0e−8, Fisher’s exact test) followed by a likely pathogenic dele-
tion (OR 8.7, 95% CI: 4.0–21.1, p: 6.5e−10, Fisher’s exact test)
and a constrained missense variant in a known developmental
disorder gene (OR 5.8, 95% CI: 3.0–11.6, p: 9.5e−9, Fisher’s exact
test) (Fig. 5b). We then analyzed if there was a signal from
damaging variants (PTVs, missenses MPC > 2 or CNVs) outside
of known ID-associated genes (termed Other high impact var-
iants). We observed a signiﬁcant enrichment of Other high
impact variants in cases vs. controls (Fig. 5a). PTVs (OR 3.0, 95%
CI: 2.2–4.2, p: 1.7e−12, Fisher’s exact test) and deletions (OR 3.5,
95% CI: 1.3–9.4, p: 5.8e−3, Fisher’s exact test) in high pLI genes
as well as constrained missense variants (OR 1.7, 95% CI: 1.3–2.2,
p: 6.7e−5, Fisher’s exact test) were signiﬁcantly enriched in the
Other high impact variants category (Supplementary Figure 6A).
As much less is known about the genetic architecture of mild
ID as compared to the more severe ID diagnoses3, we assessed if
rare variants in the same known genes contribute equally to mild
and severe forms of ID. For the analysis we combined the
moderate, severe and profound ID patients in a severe category.
The overall rates of Likely pathogenic (OR 5.4, p: 1.8e−9, Fisher’s
exact test) and Other high impact variants (OR 2.3, p: 6.5e−7,
Fisher’s exact test) were signiﬁcantly higher in the mild group
than in controls (Supplementary Figure 7A). However, severe IDs
had signiﬁcantly higher (OR: 2.4, p: 7.0e−4, Fisher’s exact test)
proportion of Likely pathogenic variants in known ID genes as
compared to mild ID (Fig. 5c, Supplementary Figure 8). For
CNVs, the diagnostic rate did not follow the same pattern of
increased likely pathogenic CNV in more severe cases than in
mild cases (Fig. 5d). This is likely because a large fraction of ID
patients who had a chromosomal abnormality had been identiﬁed
in previous clinical cytogenetic analyses and excluded from this
study.
As dysmorphic features are present more often in severe ID
than in mild ID, we analyzed if Likely pathogenic variants would
be found more often in more severe ID due to dysmorphisms and
not due to more severe ID. We repeated the enrichment analysis
of our variant classiﬁcation while restricting only to patients with
OR: 1.1, p :2.7e−01
OR: 1.2, p :6.0e−01
OR: 1.6, p :5.9e−05
OR: 1.2, p :5.8e−01
OR: 2.7, p :2.2e−12
OR: 1.2, p :1.7e−01
OR: 2.5, p :1.8e−01
Synonymous (pLI>0.95)
Case: 207/442(0.47)
Control: 970/2206(0.44)
Synonymous homozygote (pLI>0.95)
Case: 11/442(0.025)
Control: 47/2206(0.021)
Missense (MPC>2, all novel genes)
Case: 123/442(0.28)
Control: 420/2206(0.19)
Missense homozygote (CADD>20, pLI>0.95)
Case: 10/442(0.023)
Control: 42/2206(0.019)
PTV (pLI>0.95)
Case: 102/442(0.23)
Control: 224/2206(0.1)
PTV (pLI<0.95)
Case: 189/442(0.43)
Control: 863/2206(0.39)
PTV homozygote (all novel genes)
Case:3/442(0.0068)
Control:6/2206(0.0027)
0 1 2 3 4 5
Odds ratio (95% confidence intervals)
Fig. 3 Enrichment of rare variants in genes not previously associated with NDDs. Variants not observed in GnomAD or Finnish controls in novel ID genes in
cases compared to genetically matched controls (see Methods). Rate in each variant category is ﬁrst estimated for all novel genes and then after
subsetting to only novel high pLI genes. All missense variants are predicted to be deleterious (MPC > 2, see Methods). On the left the number of carriers
and total individuals are given and in parenthesis the proportion of carriers. Circles indicate the odds ratio (OR) and lines indicate the 95% conﬁdence
interval of the OR. The synonymous variant identiﬁcation comparison was performed to assess if possible differences in the variant identiﬁcation rate due
to batches/capture differences were adequately controlled. PTV protein truncating variant, CADD Combined Annotation-Dependent Depletion
pathogenicity score, pLI probability of loss of function intolerance. Source data are provided as a Source Data ﬁle
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OR: 1.3 (0.94−1.7)
p : 0.098
OR: 10 (4.8−25)
p : 3.1e−12
OR: Inf (8.6−Inf)
p : 1.8e−08 OR: 3.5 (1.3−9.3)p : 0.0058
OR: 22 (5.3−200)
p : 3.5e−08
N=85 N=177 N=34 N=9 N=17 N=2 N=14 N=0 N=12 N=9
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0.05
0.10
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a
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c
Fig. 4 Distribution of different deletion categories. a Deletion categories in ID patients showed enrichment for deletions (>100 kb) in general, and
speciﬁcally in deletions covering syndrome regions (as deﬁned by the DECIPHER database), deletions that are located in an ID-associated gene region (see
above) or CNVs deleting a gene intolerant of protein truncating mutations (pLI > 0.95). b Size distribution of Deletions by size bins, showing enrichment at
all sizes > 500 kb . c Size distribution of Duplications by size bins > 500 kb, showing an enrichment for sizes > 1 Mb. Source data are provided as a Source
Data ﬁle
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no dysmorphisms (n= 234) (Supplementary Figure 9). We
observed Likely pathogenic variants in 16/83 (19%) and 17/151
(11%) among severe ID and mild ID patients respectively (OR:
1.88, p: 0.12, Fisher’s exact test). The rate of identifying Likely
pathogenic variants was lower in non-dysmorphic, severe (19%)
and mild (11%) ID patients than in dysmorphic severe (34%) and
mild (18%) patients. There seems to be a higher rate of Likely
pathogenic variants in severe ID patients than mild ID patients
even among patients for which no dysmorphic features were
recorded, although the difference is less pronounced.
As we did not have parental exome sequencing data on all
patients, we wanted to assess if the uncertainty in Likely
diagnostic classiﬁcation affects the result that mild ID would be
less affected by de novo/ultra-rare variants in known ID genes. To
this end we subset the cases to (1) full trios with conﬁrmed de
novo in dominant acting gene (2) duos where we checked that the
other parent did not have the variant and (3) all patients with
Likely pathogenic variants. The OR in SEVERE vs. mild ID
patients having Likely pathogenic variant was OR 2.2 (0.6–9.5),
2.8 (0.9–8.8), and 2.2 (1.3–3.8) in conﬁrmed de novos, duos and
all patients respectively. This suggests that some misclassiﬁcation
would not change the conclusion that severe ID patients are more
often affected by de novos/very rare variants in known ID genes
than mild ID.
Polygenic common variant load. As we identiﬁed likely causative
variant in only 18.5% of the cases, we wanted to study the con-
tribution of the polygenic load of common variants associated to
intelligence quotient (IQ), educational attainment (EDU) and
OR:0.27, p :3.9e−28
OR: 8.07, p :8.2e−24
OR:2.05, p :3.0e−08
No damaging variant
Case: 210/433(0.48)
Control: 857/1100(0.78)
Other high impact variant
Case: 143/433(0.33)
Control: 213/1100(0.19)
Likely pathogenic variant
Case: 80/433(0.18)
Control: 30/1100(0.027)
0 5 10
Odds ratio (95% confidence intervals)
a
OR: 8.7, p :6.5e−10
OR: 11.1, p :3.0e−08
OR: 5.8, p :9.5e−09
OR: 3.6, p :4.6e−02
Deletion
Case: 29/433(0.067)
Control: 9/1100(0.0082)
PTV
Case: 21/433(0.048)
Control: 5/1100(0.0045)
Missense dominant (MPC>2)
Case: 32/433(0.074)
Control: 15/1100(0.014)
Missense recessive (CADD>20)
Case: 7/433(0.016)
Control: 5/1100(0.0045)
0 10 20 30
Odds ratio (95% confidence intervals)
b
OR: 0.74, p :0.135
OR: 2.18, p :0.003
OR: 0.83, p :0.399
No damaging variant
Severe: 79/180(0.44)
Mild: 117/227(0.52)
Other high impact variant
Severe: 56/180(0.31)
Mild: 80/227(0.35)
Likely pathogenic variant
Severe: 45/180(0.25)
Mild: 30/227(0.13)
1 2 3
Odds ratio (95% confidence intervals)
c
OR: 1.18, p :0.6926
OR: 2.86, p :0.0344
OR: 3.36, p :0.0023
OR: 0.95, p :1.0000
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Severe: 13/180(0.072)
Mild: 14/227(0.062)
PTV
Severe: 13/180(0.072)
Mild: 6/227(0.026)
Missense dominant (MPC>2)
Severe: 22/180(0.12)
Mild: 9/227(0.04)
Missense recessive (CADD>20)
Severe: 3/180(0.017)
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0.0 2.5 5.0 7.5
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d
Fig. 5 Comparison of the total rate of different classes of variants. Comparison was performed in cases vs. genetically matched controls and in mild vs.
more severe ID individuals for which both exome and CNV data was available. On the left the number of carriers and total individuals are given and in
parenthesis the proportion of carriers. Circles indicate odds ratio and lines indicate 95% conﬁdence intervals of the odds ratio estimate. a Total genetic
diagnostic rate. b Variant classes in “Likely pathogenic” variant categories. c Comparison of the rate of identifying different classes of variants in mild vs.
severe (moderate and profound ID combined) patients. d Comparison of the rate of variant types in “Likely pathogenic” category between mild and more
severe forms of ID (moderate, severe and profound ID combined). Constrained missense (MPC > 2) variants were analyzed in all genes instead of only
high pLI genes in C and D as MPC score incorporates regional missense constraint. Source data are provided as a Source Data ﬁle
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schizophrenia (SCZ) to Northern Finnish ID. There is a partial
common variant genetic overlap between cognitive function and
schizophrenia17–19 and therefore we also studied SCZ PRS. We
estimated the regional prevalence of SCZ as we did for ID and
observed a similar regional enrichment in Northern and Eastern
Finland (Supplementary Figure 1).
First, to create a reference for NFID cases, we analyzed whether
the geographical distribution of PRSs correspond to the
population history of Finland. We genotyped and imputed
14,833 individuals from the population-based FINRISK collection
and used all loci with a lead variant p-value ≤0.05 in the meta-
analyses for schizophrenia, IQ and educational attainment. To
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visualize the geographical distribution of PRSs, we used a
distance-weighted polygenic risk score in 2186 Finnish indivi-
duals who did not have any neurodevelopmental disorders and
whose parents were born within 100 km of each other (see
Methods). The PRSs for educational attainment and IQ were
lower, and for SCZ higher in the Eastern and Northern part of
Finland than in the Southern and Western Finland (Fig. 6a, c, e).
Next we asked if the PRSs were associated with ID. All PRSs were
signiﬁcantly associated with the ID phenotype as compared to
genetically matched Finnish controls (Fig. 6a, c, e). The PRS for
EDU, SCZ and IQ explained 0.94%, 0.55%, and 0.48% of the
heritability on the liability scale, respectively (see Supplementary
Figure 2 for heritability estimation using varying signiﬁcance
thresholds for locus inclusion).
We next analyzed whether PRS values were different in the
different ID groups: mild, moderate, and severe/profound
combined. The PRS for EDU was lower and for SCZ higher in
the mild ID cases compared to more severe forms, but the
differences were not statistically signiﬁcant (Supplementary
Figure 3). Unexpectedly, the IQ PRS in the mild ID group was
not signiﬁcantly different from matched population controls but
the most severe ID was different. (Supplementary Figure 3). We
also hypothesized that the EDU and IQ PRSs would be lower and
SCZ PRS would be higher in patients for which a likely causative
mutation was not identiﬁed. Thus, we compared the PRSs
between cases in different diagnostic categories but did not
observe statistically signiﬁcant differences between groups
(Supplementary Figure 4). Importantly, we also subset Likely
diagnosed patients to those for which we had conﬁrmed de novo
in a known ID gene or diagnostic CNV (n= 13). Those 13
patients were just as affected by IQ and EDU PRSs but not by
SCZ PRS (Supplementary Figure 4). Assuming we had sufﬁcient
power, this suggests that in addition to high penetrance variants,
a more general polygenic component (ID and EDU PRS) also
contributes to the genetic background of ID.
Variants enriched in Finland. Finally, we asked if some variants
enriched in Finland might contribute to the Northern Finnish ID
phenotype as variants with reduced reproductive ﬁtness can exist
in markedly higher frequency in a population with a recent
bottleneck9. We hypothesized that some of these variants would
be associated with ID in the NFID cohort. To identify these
variants, we compared the allele frequencies in Finnish samples to
the allele frequency in non-Finnish Europeans in the GnomAD
database. PTV and missense variants in the range of 0.1–5%
(Supplementary Figure 10) were proportionally more enriched
compared to other variants. This is in line with our previous
observation in smaller datasets8.
Dominant variants enriched in Finland. We ﬁrst analyzed low
frequency and rare (MAF < 0.1% in GnomAD non-Finnish
population maximum) single missense and PTV variants enri-
ched at least two-fold in Finland or absent in GnomAD non-
Finns excluding singletons (13,483 variants; 12,628 missense, 855
PTV). We identiﬁed 396 variants nominally (p < 0.05, Fisher’s
exact test) associated with ID (Supplementary Data 4). We then
aimed to replicate these associations in NDD cases and geneti-
cally matched controls from the Northern and Southern Finland
(Table 2). After meta-analyzing all three cohorts, we identiﬁed 29
variants associated with a p-value < 0.001 (Mantel–Haenzel test)
(20 variants were found in cases only across the three cohorts).
However, none of variants surpassed a Bonferroni multiple-
testing correction for 13,483 tests.
Recessive variants enriched in Finland. We next asked if some of
the enriched PTV or missense variants with low allele frequency
in GnomAD (AF < 0.01) were recessively associated with ID. We
excluded singleton homozygotes and variants observed as
homozygous in GnomAD. After these ﬁltering steps we per-
formed a recessive analysis for 1408 variants (1379 missense
variants and 29 PTVs). Eighteen variants were observed as
homozygous more than once in cases across the three cohorts but
not in controls (Table 3).
We identiﬁed a homozygous missense variant in the CRADD
gene in three independent ID cases. Additionally, we identiﬁed
one CRADD missense homozygote in the Northern Finland NDD
case cohort (RAFT meta p: 5.75E−8). The variant is over 50 times
more frequent in Finland than in non-Finnish Europeans. The
variant is located in the DEATH domain through which CRADD
interacts with other DEATH domain proteins20. Another variant
in the HGF gene achieved a p-value surviving Bonferroni
correction (p: 1.3e−5, RAFT meta), but it was observed only in
two cases. Homozygote variants in HGF have been identiﬁed in
consanguineous families ascertained for non-syndromic deaf-
ness21. Our cases did not have hearing problems. Among the 18
genes with case-only recessive candidate variants we observed
signiﬁcantly more genes that are intolerant of homozygote PTV
variation (pRec > 0.822) than expected by chance. A pREC metric
was available for 17 of the 18 of the candidate genes, of which
eight were intolerant of homozygote PTV variation. In ExAC
4,508 out of 18,241 genes have pRec > 0.8, and therefore we would
expect 4.2 genes by chance (binomial test p-value 0.046). This
suggests that some of the 18 candidate variants are true risk
variants for ID (see Supplementary Data 6 for all 57 nominally
signiﬁcant associations).
Variance explained by different variant categories. To put the
relative contribution of different classes of genetic variation to a
context, we estimated the variance explained by each signiﬁcant
category in the case–control comparisons. We added the three
CRADD homozygotes to the likely pathogenic category as we
clearly demonstrated the variant to be a causative recessive var-
iant (Table 3). For likely diagnostic and other high impact var-
iants, we used genetically matched cases and controls for which
both exome and CNV data were available (433 cases and 1100
controls). For the polygenic risk score, we used 439 cases and
2195 genetically matched controls. As we observed geographical
differences in PRSs within Finland, we corrected the variance
explained estimation using the ﬁrst four PCs. The PRS’s con-
tribution to heritability is lower (IQ 0.48%, 95% CI: 0.067–1.25%;
Fig. 6 Regional distributions of PRSs within Finland and between cases and contols. a Locally weighted educational attainment PRS distribution in Finnish
population controls whose parents birthplace is within 100 km of each other. b Educational attainment PRS in cases and all population controls and
genetically matched population controls. c Locally weighted schizophrenia PRS distribution in Finnish population controls whose parents birthplace is within
100 km of each other. d Schizophrenia PRS in cases and all population controls and genetically matched population controls. e Locally weighted IQ PRS
distribution in Finnish population controls whose parents birthplace is within 100 km of each other. f IQ PRS in cases and all population controls and
genetically matched population controls. Error bars indicate 95% conﬁdence intervals around mean. Y-axis is in SD units of PRS standardized to all
population controls. Source data are provided as a Source Data ﬁle
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SCZ 0.55%, 95% CI: 0.078–1.5%; EDU 0.94%, 95% CI:
0.31–1.92%) than that of pathogenic variants in known genes
(4.15%, 95% CI: 2.78–5.77%) or other high impact variants
(2.25%, 95% CI: 1.30–3.52%) (Fig. 7a). When comparing the
different ID severities, the heritability explained for PRSs was the
highest in mild ID for EDU (2.1%, 95% CI: 0.46–4.5%) and
smaller in more severe ID (0.52%, 95% CI: 0.04–1.60%). The
heritability estimation for all PRSs and ID categories is presented
in Supplementary Figure 11.
The variance explained by Likely pathogenic variants in known
genes was slightly higher in more severe ID (6.2%, 95% CI:
3.8–9.1%) than in mild ID (4.0%, 95% CI: 1.8–7.1%). This is
expected as we observed a signiﬁcantly lower proportion of Likely
pathogenic variants in mild ID (13%) vs. more severe ID (25%)
(Figs. 5 and 7b).
Discussion
Here we have described a comprehensive genetic analysis of an
ID cohort from a population with a relatively high prevalence of
ID. We studied the contribution of SNVs and INDELs, CNVs,
and of a genome-wide common variant polygenic load. Unlike
most published studies our ID cohort consists mostly of relatively
mild ID cases. We identiﬁed a likely pathogenic variant in genes
known to be associated with ID in 18% of the cases for which
both exome and CNV data were available (Fig. 5a), explaining an
estimated 4.2% of the heritability (Fig. 7). Additionally, we
observed a signiﬁcant ~2-fold enrichment of damaging variants/
CNVs in loss-of-function intolerant genes not yet linked to ID,
which explained an additional 2.3% of the heritability (Figs. 5a
and 7). We then demonstrated that a common variant polygenic
load is associated with ID. We observed educational attainment,
IQ and schizophrenia polygenic risk scores to be associated with
ID explaining an estimated 0.94%, 0.48%, and 0.55% of the
heritability, respectively.
We then focused on characterizing the genetic architecture of
mild vs. more severe forms of ID and observed that a likely
causative variant in known ID genes was signiﬁcantly more
often identiﬁed in more severe ID cases than in mild ID cases
(Fig. 5c). This suggests that either mild ID has a more complex
etiology or that variants in genes predisposing to mild ID are
partly different than those predisposing to more severe forms of
ID. Our observation is in agreement with epidemiological stu-
dies where mild ID has been suggested to represent a highly
heritable low end of a normal distribution of IQ whereas severe
ID is a distinct condition with different etiology5. Therefore,
mild ID should have less contribution from de novo and
extremely rare variants, which have been the major focus of
most genetic studies of ID.
To study the possibly more complex etiology of mild ID, we
ﬁrst showed that the polygenic risk score of low educational
attainment, low IQ, and schizophrenia were all higher in the
Eastern and Northern parts of Finland, coinciding with the more
recent bottleneck and higher prevalence of intellectual disability
Table 3 Homozygous Finnish enriched variants observed ≥2 times across NFID and the Southern and Northern Finnish NDD
cases and not observed in any controls as homozygous
Variant Gene Previous evidence GnomAD
Finnish
AF
GnomAD
pop. Max
AF
NFID AF RAFT
meta p
NFID
case
homs
NFID
RAFT
p
Population
NDD case
homs
Population
NDD RAFT
p
12:94243956
G:A (mis)
CRADD AR Lissencephaly, ID25 6.01E−3 9.15E−4 7.83E−3 5.01E−8 a 3 1.86E−6 1 9.30E−3
7:81374424 G:
C (mis)
HGF AR hearing loss
(OMIM)
1.12E−3 5.48E−4 2.52E−3 1.34E−5 a 1 3.20E−3 1 2.54E−3
12:15784582 T:
C (mis)
EPS8 AR deafness (OMIM)
Cognition defects in
mice51
9.03E−3 1.30E−3 6.89E−3 1.28E−4 2 1.28E−4 0 NA
1:220236134
C:T (mis)
BPNT1 - 1.07E−2 4.83E−3 6.89E−3 1.34E−4 2 1.34E−4 0 NA
7:1520077 T:C
(mis)
INTS1 AR ID26 1.30E−2 3.05E−3 1.71E−2 1.95E−4 3 1.95E−4 0 NA
2:95753239 A:
G (mis)
MRPS5 - 9.87E−3 4.56E−3 8.29E−3 2.88E−4 2 2.88E−4 0 NA
10:123844296
C:A (mis)
TACC2 - 1.32E−2 1.10E−3 1.14E−2 1.05E−3 2 1.05E−3 0 NA
1:155028692
C:T (mis)
ADAM15 - 8.69E−3 2.37E−3 1.18E−2 2.11E−3 1 4.84E−2 1 3.58E−2
18:14542688
G:A (mis)
POTEC - 1.86E−2 6.26E−3 1.98E−2 2.11E−3 2 1.01E−2 1 1.65E−1
21:19651329 G:
C (mis)
TMPRSS15 Enterokinase deﬁciency
(OMIM)
1.73E−2 6.31E−3 1.93E−2 2.66E−3 1 1.42E−1 2 9.85E−3
15:60789800
T:C (mis)
RORA AD ID52 1.02E−2 9.14E−4 1.59E−2 4.03E−3 1 9.35E−2 1 3.38E−2
11:6023849 C:
T (mis)
OR56A4 - 1.69E−2 1.82E−3 1.61E−2 4.45E−3 2 4.45E−3 0 NA
11:3681309 G:
A (mis)
ART1 - 1.64E−2 3.68E−3 1.53E−2 5.67E−3 1 8.43E−2 1 5.76E−2
19:56424477
TC:T
(frameshift)
NLRP13 - 1.65E−2 1.28E−3 1.40E−2 6.07E−3 1 7.44E−2 1 8.54E−2
8:17612739 G:
C (mis)
MTUS1 - 1.46E−2 2.01E−3 1.54E−2 6.74E−3 1 9.22E−2 1 7.45E−2
1:183520048
A:T (mis)
SMG7 NMD-components
linked to ID53
2.49E−2 1.10E−3 2.62E−2 3.85E−2 1 2.85E−1 1 1.58E−1
X:23410887 C:
T (mis)
PTCHD1 x-linked ID/AUTISM54 2.43E−4 2.51E−5 2.27E−4 NA 1b NA 1b NAb
AR autosomal recessive, AD autosomal dominant, ID intellectual disability, AF allele frequency, mis missense
aSigniﬁcant after multiple testing correction
bRAFT statistic not valid for X-chromosome. Both carriers are hemizygote males
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and schizophrenia within those regions in Finland10. We then
showed that the PRS for educational attainment, intelligence and
SCZ all were signiﬁcantly associated with ID in our cohort when
compared to the genetically matched control population, thereby
demonstrating the contribution of common low-risk variants to
intellectual disability. This observation could be in part because
most of our ID patients had mild ID. Indeed, the highest herit-
ability explained (2.1%) was observed with EDU PRS in mild ID.
The EDU PRS has been reported to explain 2.9% of the herit-
ability of educational attainment in a population sample inde-
pendent of the original GWAS23. Our results suggest that mild ID
might be just a continuum of the population distribution of
cognitive capacity and support the hypothesis of the polygenic
background. The observation that the heritability explained by
EDU PRS is clearly smaller in severe ID (0.5%) supports the
earlier epidemiological ﬁndings that the genetic background of
severe ID is different from mild ID5, where penetrant mutations
contribute more to the phenotype.
The PRS for IQ was only slightly below the matched controls in
mild ID. This was unexpected. The reason remains speculative,
but could be contributed by the fact that the IQ PRS was gen-
erated from a smaller study samples (n= 78,308) than the EDU
score (n= 293,723).
After observing a signiﬁcant association between the common
variant load and ID, we hypothesized that PRSs would be dif-
ferent in those individuals in whom a likely pathogenic variant
was identiﬁed and those where such variants were not identiﬁed.
However, such a difference was not observed, not even a sug-
gestive trend (Supplementary Figure 4). This observation could be
explained by assuming that rare high-risk variants and the
common variant load act additively to increase the risk of ID.
Another explanation could be that there still might be other
unidentiﬁed strong or moderate variants explaining the pheno-
type in many of the cases in which we did not identify a causative
variant. We explored this hypothesis by grouping patients into
the Other high impact variant category if they carried a PTV,
CNV or damaging missense mutation in loss of function intol-
erant genes not previously linked to NDDs, but did not observe a
difference in PRSs in that group either (Supplementary Figure 4).
An additive effect of high impact rare variants and common
variant polygenic load has recently been suggested in the genetic
etiology of ASD24, our data suggest a similar genetic architecture
for ID.
Finally, we studied if some variants enriched in Finland in the
relatively recent bottleneck would be associated with ID in our
cohort. We conclusively identiﬁed a recessive variant in the
CRADD gene enriched in Finland in three NFID patients and one
NDD patient from the population NDD cohorts (Table 3). The
allele frequency of this variant is 50× higher in the Finnish
population than in non-Finnish Europeans. Recently recessive
variants in CRADD have been reported in six patients from four
families with megalencephaly, frontal predominant pachygyria,
intellectual disability, and seizures25. All three of our patients had
pachygyria, consistent with previously reported cases25. One of
the patients identiﬁed in Di Donate et al. had Finnish origins and
carries exactly the same homozygotic variant as our patients,
clearly demonstrating that the variant is a causal for a speciﬁc
syndrome. We also observed three cases that had the same mis-
sense variant in homozygous state in the INTS1 gene (Table 3).
Recently a loss-of-function variants in INTS1 have been identiﬁed
in three unrelated moderate to severe ID patients26. One of our
patients had mild ID and the two others had moderate/severe ID.
In the dominant association analysis of Finnish enriched var-
iants, none of the variants surpassed multiple testing correction
(Supplementary Data 5). However, one variant among the top 10
variants, a missense variant in the DENR gene, was totally absent
in non-Finnish GnomAD individuals, is very rare in the Finnish
population but enriched in Northern Finland (6.3 × 10-4 in
GnomAD Finns; 9.7 × 10-4 in our Northern Controls and 3.1 ×
10-4 in Southern controls). The variant replicated in the Northern
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Fig. 7 Estimate of heritability explained by different variant categories on liability scale. a Variance explained by genetic categories in all ID cases.
b Variance explained delineated by ID severity. Variance explained was estimated by Nagelkerke r2 while controlling for the ﬁrst four PCs. 95% Conﬁdence
intervals of variance explained were estimated by 5000 bootstrap samples. Source data are provided as a Source Data ﬁle
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NDD cohort and was extremely rare in Southern Finnish NDD
cases and controls (1/322 in cases and 1/1594 in controls) but had
a high OR estimate consistent with associations in NFID and
Northern NDD samples. Two DENR de novo missense variants
have previously been identiﬁed in patients ascertained for autism
spectrum disorder27,28. The case in Neale et al. had an IQ of 67
and the case in Haas et al, had a language delay and poor com-
prehension. Two of the three DENR variant carriers in the NFID
cohort had a suspected or conﬁrmed ASD diagnosis. Eight indi-
viduals in the population NDD cases were schizophrenia patients.
The SCZ cases had low scores on processing speed and verbal
learning cognitive tests as compared to population controls
(Supplementary Figure 10). ID or autism were not systematically
diagnosed in the collection. Further studies are needed to con-
clusively determine if some of the other identiﬁed candidate genes
are truly ID associated.
Limitations of the study includes the fact that we used exome
sequencing although non-coding rare variants also contribute to
the etiology of ID29. Also, we did not have exome sequencing for
parents for 2/3 of the patients, but we performed sensitivity
analyzes on the subset of patients, where we had full trios. These
supported the conclusions that common variant polygenic load
and rare variants might act additively and that mild ID is less
affected by de novo/extremely rare variants in known ID genes
(see total genetic diagnosis rate chapter and Supplementary
Figure 4).
In conclusion, we demonstrate that a common variant poly-
genic load is a contributing factor in ID and more broadly
characterized the genetic architecture of mild ID, which so far has
been understudied. We also show that some damaging variants
enriched in frequency in Finland contribute to intellectual dis-
ability and provide, yet another example of the power of utilizing
population isolates such as Finland in disease gene mapping.
Methods
Samples. Since January 2013 subjects for the NFID (Northern Finland Intellectual
Disability) project have been recruited from the Northern Ostrobothnia Hospital
District Center for Intellectual Disability Care and from the Department of Clinical
Genetics of Oulu University Hospital. In January 2016 the recruitment was
expanded to include all pediatric neurology units and centers for intellectual dis-
ability care in the special responsibility area of Oulu University Hospital. Subjects
of all ages with either intellectual disability or pervasive and speciﬁc developmental
disorders (ICD-10 codes F70-79 and F80-89, respectively) of unknown etiology
were included. Individuals with copy number variations of unknown clinical sig-
niﬁcance or highly variable phenotypes were also included in order to uncover
other possible factors of genetic etiology. Subjects were identiﬁed through hospital
records and invited via mail to take part in the study. In addition, they were
recruited during routine visits to any of the study centers.
The cases have been evaluated and examined clinically by multi-professional
teams. Depending on the situation in question the team may consist of
psychologist, physician, speech and occupational therapist, physiotherapist, nurse
and social worker. Standardized IQ tests that were used included different versions
of following tests: Wechsler Preschool And Primary Scale Of Intelligence (WPPSI),
Wechsler Intelligence Scale for Children (WISC) and Wechsler Adult Intelligence
Scale (WAIS) for adults.
In case of autism spectrum disorder the diagnoses were also based on
multiprofessional evaluation and different, clinically used methods such as ADOS
(Autism Diagnostic Observation Schedule), ADI-R (Autism Diagnostic Interview),
and CARS (Childhood Autism Rating Scale).
All research subjects and/or their legal guardians provided a written informed
consent to participate in the study. DNA samples from the participants were
extracted primarily from peripheral blood. In a few cases where a blood sample
could not be obtained, DNA was extracted from saliva. The ethical committees of
the Northern Ostrobothnia Hospital District and the Hospital District of Helsinki
and Uusimaa approved the study.
Clinical diagnostic tests varied considerably depending on the subject´s age,
clinical diagnosis and phenotype. During the past 20 years, blood and urine
metabolic screening tests, chromosome karyotyping, FMR1 CGG repeat analysis,
electroencephalography (EEG) and brain computed tomography (CT) or magnetic
resonance imaging (MRI) have been routinely performed on almost all individuals
with remarkable developmental delay or intellectual disability. Array CGH and
whole exome sequencing have been widely used for less than ten and three years,
respectively.
Identiﬁcation of other neurodevelopmental disorder cases. We identiﬁed
individuals with neurodevelopmental disorder (NDD) phenotypes (intellectual
disability, schizophrenia, autism and epilepsy; N= 636, NFNDD and SFNDD cases
in Table 2) among 5904 individuals with exome sequence data in the FINRISK
study. FINRISK is a series of population-based health examination surveys carried
out every 5 years since 1972 to monitor the risk of chronic diseases30. The cohorts
have been followed up for disease end-points using annual record linkage with the
Finnish National Hospital Discharge Register and the National Causes-of-Death
Register.
Additional Finnish NDD cases were included from cohorts of schizophrenia
and autism patients sequenced as part of the UK10K-study (i.e. subcohorts
UK10K_NK_SCZ, UK10K_KUUSAMO_SCZ and UK10K_ASDFI) and a
collection of autism patients from Southern Finland (AUTISM_ASDFI) (see
Supplementary Data for cohort descriptions). We genetically matched each NDD
case to ﬁve exome sequenced controls using the ﬁrst 2 principal components (PCs).
We further divided these cases and controls approximately to Northern Finnish
NDD (NFNDD, Northern Finland NeuroDevelopmental Disorder) and Southern
Finnish NDD (SFNDD, Southern Finland NeuroDevelopmental Disorder) cohorts
based on principal component analysis (PCA).
Regional prevalence of intellectual disability in Finland. To estimate regional
prevalence of ID and SCZ in Finland, we used The Social Insurance Institution of
Finland provides social security coverage for Finnish residents. The Social Insur-
ance Institution of Finland centrally provides all disability pensions in Finland and
maintains a database of all residents on a disability pension and the reason for the
pension. We requested the number of individuals over 16 years of age receiving a
disability pension for ID or schizophrenia (SCZ) at the end of year 2016 in each of
the 19 high-level administrative regions in Finland. We divided the number of
beneﬁciaries by the population aged over 16 in each region to get a crude estimate
of the relative prevalence of more severe SCZ and ID cases. The prevalence of
schizophrenia particularly is higher in more detailed prevalence estimaties11.
Schizophrenia tends to be underdiagnosed in the ﬁrst years of illness31, and only
50% of patients with schizophrenia receive a disability pension after 5 years of
initial diagnosis32.
CNV analysis. To analyze the copy number variations (CNVs), we performed
DNA Chip Array (Illumina HumanCoreExome v 12.0, Illumina PsychArray) based
copy number analysis of 497 cases and 504 unaffected family members of the NFID
cohort. To assess CNV frequencies in the general population, we used as controls a
population-based cohort of 13,390 participants from the FINRISK study33. CNV
calls in controls were generated using raw data from the Illumina HumanCor-
eExome v12.0 and v12.1 chips.
CNVs were called using a CNV pipeline powered by PennCNV34 for sensitive
CNV calling. Adjacent CNVs of similar copy number were called as one if the
adjoining region between the two calls was ≤20% of the joined CNV. To increase
the conﬁdence in the called CNVs, we considered only CNVs supported by at least
10 consecutive probes and which covered a genomic region of at least 100 kb,
omitting known CNV artifacts regions35. The large regional requirement was set to
support analysis across the different DNA chips.
Samples were excluded if they had: (1) a high variance (SD > 0.3) in intensity
(1.5% in NFID; 5.6% in FINRISK), (2) a high (>0.005) drift of B allele frequency
(0 additional samples in NFID; 0.2% in FINRISK), and (3) CNVs called in excess
of 10 for one individual (10 samples in NFID; 8.9% in FINRISK). All called CNVs
for the NFID cohort, both for patients and for unaffected family members, were
manually curated. For the FINRISK population cohort, CNVs were manually
curated if large (>500 kb) or if they ﬁt into a category of interest relevant to study
(see Identifying likely pathogenic mutations chapter below). Otherwise, CNVs of
controls were rejected if at least 50% of the CNV overlapped a known artifact
region36, or had a poor coverage (≤1.08 SNPs per 10 kb).
GWAS data processing. All samples were genotyped in seven batches on either
the Illumina CoreExome or Illumina PsychArray, which contains 480,000 common
variants. The NFID samples were genotyped in three batches, one with Illumina
CoreExome and two with PsychArray. FINRISK population controls were geno-
typed in ﬁve batches using Illumina CoreExome.
We excluded markers that exhibited high missingness rates (>5%), low minor
allele frequency (<1%), or failed a test of Hardy–Weinberg equilibrium (p < 1e−9).
We also excluded individuals with high rates of heterozygosity (>3sd from the
mean), or a high proportion of missing genotypes (>5%). To control for population
stratiﬁcation, we merged the genotypes from individuals passing QC with HapMap
III data from European (CEU), Asian (CHB+ JPT), and African (YRI)
populations. We then performed a PCA on this combined data and excluded
population outliers not clustering with the Finnish samples
We then merged genotyping batches one-by-one and repeated the QC
procedures described above on the merged dataset. To prevent any potential batch
effects in the merged data, we also excluded any markers that failed a test of
differential missingness (p < 1e−5, Fisher’s exact test) between the merged batches.
Furthermore, during each round of merging we performed a association analysis
(using a logistic mixed-model for individuals) between samples from each batch to
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identify markers where the minor allele frequency deviated signiﬁcantly between
batches (p < 1e−5, score test). Finally, we removed related individuals (identity by
descent > 0.185).
We used a custom Finnish imputation reference panel containing 1941 low-pass
whole genomes (4.6×) and 1540 high coverage exomes. We used Shape-IT37 for
pre-phasing and Impute-238 for imputation.
Exome sequencing. NFID cases were exome sequenced at the Broad Institute
using Illumina Nextera Rapid Capture Exome-capture kit and sequenced with
Illumina HiSeq2000 or 2500. NFID cases were jointly called with a collection of
Finnish individuals collected as part of the Sequencing Initiative Suomi (SISU)-
study (www.sisuproject.ﬁ). The sequence data processing and variant calling has
been described previously39. See Supplemental Note 1 for descriptions of cohorts
used in the current study.
We ﬁltered samples with estimated contamination > 3% (n= 590), chimeric
reads > 3% (n= 51), samples signiﬁcantly deviating from other samples within
each project/batch on selected metrics (transition/transversion ratio, insertion/
deletion ratio, heterozygous/homozygous variant ratio, number of singletons, n=
243) and ﬁnally included only those with empirically conﬁrmed ≥99% Finnish
ancestry (described in Rivas et al.39).
We ﬁrst split the multiallelic variants in to bi-allelic variants. For genotype QC,
we set the following genotypes to missing; genotype quality (GQ) < 20, read depth
(DP) < 10, heterozygote allelic balance less than 20% or greater than 80%,
homozygous reference alt reads ≥10%, alternate allele homozygous reference reads
≥10%. Variants were ﬁltered out if Variant Quality Score Recalibration (VQSR) did
not indicate PASS, the p-value from a test of Hardy–Weinberg Equilibrium
(pHWE) < 1e−9 in controls (in females only in the X chromosome), SNP quality-
by-depth (QD) < 2, INDEL QD < 3 or more than 20% of heterozygote calls had
allelic balance out of the 20–80% range. To account for the different batches of
exome sequencing we required a stringent genotype call rate ≥0.95 in cases and
controls separately after genotype QC. All variant and genotype QC was performed
using Hail40 and executed in the Google Cloud dataproc cluster.
Finally, we ensured cases and controls were approximately independent by
ﬁltering such that all samples had a pairwise kinship coefﬁcient < 0.0442 to every
other sample. We estimated kinship coefﬁcient using King41 and when possible we
always retained cases rather than a related control (N ﬁltered= 1531).
Variant annotation. We annotated variants using VEP v.85 and the LOFTEE VEP
plugin [https://github.com/konradjk/loftee] to ﬁlter likely false positive protein
truncating variants (PTV). We considered variant annotations of the canonical (as
deﬁned by ENSEMBL) transcript only. A variant was considered to be a protein
truncating variant (PTV) if LOFTEE predicted it to be a high conﬁdence loss-of-
function variant (stop-gained, splice site disrupting or frameshift) without any
warning ﬂags.
Identifying likely pathogenic mutations. As a basis for identifying Likely
pathogenic variants, we used a gene list curated within the Deciphering Develop-
mental Disorders study (DDD) and a gene list of 93 exome-wide signiﬁcant genes
from the latest DDD study meta-analysis of de novo variants4. We downloaded a
gene list curated within the DDD study [https://decipher.sanger.ac.uk/
ddd#ddgenes] containing 1897 genes with varying degrees of evidence of mutations
in those genes causing developmental delays. We further subset the list to only
conﬁrmed or probable developmental delay genes contributing to a brain/cognition
phenotype. This gene set was further extended by a set of 93 genes with a sig-
niﬁcant excess of damaging de novo variants in the latest DDD meta-analysis4.
These two lists resulted in a total of 818 genes (Supplemental Table 1). For each ID
patient we searched for PTV or damaging missense (MPC ≥242) variants not
observed (as homozygotes in recessive genes) in non-Finnish GnomAD individuals
or in our control individuals. We used only non-Finnish GnomAD individuals, as
all Finnish individuals in GnomAD are included in our control exome cohort.
Variants were classiﬁed as Other high impact variants if the variant was a PTV (in
PTV constrained gene, pLI22 > 0.95) or a damaging missense variant (MPC ≥2) in a
gene that was not in the list of known genes (as above) and not observed in non-
Finnish GnomAD individuals or in our control individuals. For homozygotes we
used CADD43 score > 20 to ﬁlter to putatively damaging variants, as MPC score is a
measure of heterozygous constraint.
CADD was chosen as pathogenicity prediction method as CADD integrates
multiple different prediction tools in to a single prediction score. CADD contains
both conservation-based methods (e.g., GERP, Phastcons) as well as protein level
scores (e.g., SIFT and Polyphen)43.
In homozygote variant ﬁltering we required that the variant was not seen as
homozygous in non-Finnish GnomAD samples or in our internal Finnish controls.
In cases where we had parental exome data we further ﬁltered the “likely
pathogenic” variants if they were inherited from control parent or if clinical
phenotype was clearly different than what has been reported in the literature (as
assessed by clinical geneticist).
The algorithm for identifying pathogenic mutations was implemented in Hail40
and executed in a Google Cloud dataproc cluster.
All CNVs passing QC criteria were classiﬁed as either (1) likely pathogenic, (2)
other high impact variant, or (3) uncertain. A “likely pathogenic” classiﬁcation was
assigned to deletions where the size was at least 1 Mb, and 500 kb for de novo
deletions. All CNV types were additionally considered likely pathogenic (class i)
when overlapping at least 75% with an established disease associated locus44, or
deleting an ID associated gene of interest (see above). CNVs were classiﬁed as
“other high impact variant” (class 2) if both: (A) they were never seen in unaffected
family members, population controls, or the high-quality variant set of the
Database of Genomic Variants; and (B) they deleted a gene with a high probability
of loss-of-function intolerance22 (pLI > 0.95). Otherwise, a CNV was classiﬁed as a
variant of uncertain signiﬁcance (class 3).
Polygenic risk scores. As SNP weights we used summary statistics from GWA
studies of schizophrenia45, IQ17, and educational attainment18. To avoid potential
biases caused by non-random regional sampling of individuals in the GWA studies
the summary statistics were generated after excluding all Finnish cohorts.
For polygenic scoring we used only well-imputed and genotyped common SNPs
(Impute 2 info ≥0.9, allele frequency > 0.05). We pruned the SNPs to a subset of
uncorrelated SNPs (r2 < 0.1 within 500 kb) and used the remaining SNPs for
calculating a polygenic risk score (PRS) for each individual by summing the
product of beta from the summary statistics and the number of effect alleles
(genotype dosage for imputed SNPs) over all SNPs. Our primary hypothesis testing
used a PRS constructed from nominally signiﬁcant variants (p < 0.05) in the
original GWAS study. The genetic scores were standardized to z-scores using
Finnish population controls.
For visualizing geographical differences in the PRSs within Finland, we subset
the controls to those whose parents’ birthplaces were within 100 km of each other.
An individual’s coordinates were set to the average of the parents’ birthplaces’
longitude and latitude. We smoothed the PRS across a map of Finland. At each
map position we calculated weighted average by weighting each individual’s PRS by
the inverse of the squared distance between the map point and the individual’s
coordinate. Individuals within 50 km from the map point contributed equally to
the map point, i.e., the full weight was given to those individuals independent of
their exact distance from the map point.
Association analysis. To control for population stratiﬁcation, we matched each
case to its ﬁve genetically closest controls given by the ﬁrst two PC’s using the
optmatch R package.
For replication and for studying the neurodevelopmental spectrum of candidate
variants in the exome analysis, we identiﬁed neurodevelopmental (NDD) cases (ID,
SCZ, and ASD) from the Finnish FINRISK population cohort as well as disease-
speciﬁc collections sequenced in the UK10K study (SCZ and ASD) (Table 2). Each
NDD case was genetically mapped to its ﬁve closest controls that were not matched
to NFID patients.
For the dominant association analysis, we used both Fisher’s exact test and Firth
bias corrected logistic regression using the four ﬁrst PC’s as covariates. We meta-
analyzed the results across the three cohorts (NFID, North NDD and South NDD)
using Mantel–Haenzel meta-analysis (rma.mh in metaphor46 R package) for
Fisher’s analysis and a sample size weighted meta-analysis for Firth47.
For the recessive analysis we used a recessive allele frequency test (RAFT)48,
which takes the population allele frequency of the variant tested into account to
estimate the probability of observing as many cases and controls as homozygotes
under the null. As we genetically matched all cases to controls we present the
analysis results from Fisher’s exact test and present Mantel–Haenzel meta-analysis
and Firth results in the supplement.
Association analyses were performed using Hail40 and executed in a Google
Cloud dataproc cluster.
Enrichment analysis. For testing if different classes of variants were enriched in
cases vs. controls we used Fisher’s exact test and for signiﬁcant variant classes we
estimated the variance explained by Nagelkerke’s pseudo r2.
For the CNV analysis, we used the same cases and controls as in the exome
analysis where GWAS data was available (433 cases and 1100 controls passing QC
for CNV analysis). Association analysis was performed testing carrier ratios using
Fisher’s exact test. The relevant categories were: (1) CNVs overlapping one of
DECIPHER’s syndromic regions (2) deletions overlapping a known developmental
delay gene (Supplementary Data 1), and (3) deletions overlapping a gene with high
probability of protein truncating variant intolerance (pLI > 0.95)22.
Heritability estimation. We estimated the variance explained by different variant
categories by ﬁtting a logistic model and computing Nagelkerke’s pseudo r2 from
the ﬁtted full and null models.
Case/control status was used as a dependent variable and as an explanatory
variable we used either a binary indicator for presence of variant in a given category
(likely diagnostic or other high impact) or a continuous variable for PRS variance
estimation. As we observed geographical differences in all evaluated PRSs we
corrected for the ﬁrst four PCs even after genetic matching of cases and controls to
account for any residual stratiﬁcation (i.e., the null model included the ﬁrst four
PCs). Conﬁdence intervals for r2 were estimated using adjusted bootstrap
percentile method49 by drawing 5000 bootstrap samples and computing the r2 for
each sample. We compared the variance explained for the whole ID cohort and also
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in mild and severe ID separately. As mild and severe ID have different population
prevalence we transformed the observed scale variance explained to the liability
scale50. We used the population prevalence from a cumulative normal distribution
function with mean 100 and standard deviation 15. Prevalence of 1.94%, 1.91% and
0.034% were used for all ID (IQ < 70), mild ID (50 ≤ IQ < 70) and other more
severe ID combined (IQ < 50), respectively.
Code availability. All code used within the manuscript for all analyses is available
from the corresponding author upon reasonable request.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All summary level data are available from the corresponding author on reasonable
request. The datasets generated during and/or analysed during the current study
are not publicly available due to patient conﬁdentiality and multiple different
consents of population cohorts used but subset of the data are available from the
corresponding author on reasonable request. A reporting summary for this Article
is available as a Supplementary Information ﬁle. The source data underlying Figs. 2,
3, 4, 5, 6b, d, f and 7 and Supplementary Figs 2-9 are provided as a Source Data ﬁle.
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